For others, particularly those with significant obesity-related health conditions, the potential benefits of earlier access justify the additional risks of the research market
Gordon-Williams R, Harris C, Magee DJ
Cardiovascular Outcomes Semaglutide has demonstrated cardiovascular benefits, including a reduction in major adverse cardiovascular events (MACE) such as heart attack and stroke in patients with type 2 diabetes at high cardiovascular risk
Patients are also most likely to experience problems when they start on the drug or when they step up to a higher dosage
Having said that, compounded semaglutide can be a helpful option during Ozempic and Wegovy shortages , as well as for people who cannot take Ozempic and Wegovy in their standard form
While the accessibility may seem convenient, it introduces a range of risks that most people do not fully consider before they start